Bibliography
- Dye C, Williams BG, Espinal MA, Raviglione MC. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Sciencsze 2002;295(5562):2042-46
- Cosma CL, Sherman DR, Ramakrishnan L. The secret lives of the pathogenic mycobacteria. Annu Rev Microbiol 2003;57:641-76
- Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001;19:93-129
- WHO Executive Board. XDR-TB–a global threat. The Lancet 2006
- Brewer TF. Preventing tuberculosis with bacillus Calmette-Guérin vaccine: a meta analysis of the literature. Clini. Infec. Diseases 2000;31(Suppl 3):S64-67
- Gupta UD, Katoch VM, McMurray DN. Current status of TB vaccines. Vaccine 2007;25(19):3742-51
- Babiuk LA, Pontarollo R, Babiuk S, et al. Induction of immune responses by DNA vaccines in large animals. Vaccine 2003;21(7-8):649-58
- Jechlinger W. Optimization and delivery of plasmid DNA for vaccination. Expert Rev Vaccines 2006;5(6):803-25
- Lowrie DB, Tascon RE, Colston MJ, Silva CL. Towards a DNA vaccine against tuberculosis. Vaccine 1994;12(16):1537-40
- Tascon RE, Colston MJ, Ragno S, et al. Vaccination against tuberculosis by DNA injection. Nat Med 1996;2(8):888-92
- Lowrie DB, Tascon RE, Bonato VL, et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999;400(6741):269-71
- Bonato VL, Goncalves ED, Soares EG, et al. Immune regulatory effect of pHSP65 DNA therapy in pulmonary tuberculosis: activation of CD8+ cells, interferon-γ recovery and reduction of lung injury. Immunology 2004;113(1):130-38
- Nuermberger E, Tyagi S, Williams KN, et al. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am J Respir Crit Care Med 2005;172(11):1452-56
- Illum L. Nasal drug delivery–possibilities, problems and solutions. J Control Release 2003;87(1-3):187-98
- Lima KM, Santos SA, Lima VM, et al. Single dose of a vaccine based on DNA encoding mycobacterial hsp65 protein plus TDM-loaded PLGA microspheres protects mice against a virulent strain of Mycobacterium tuberculosis. Gene Ther 2003;10(8):678-85
- O'Hagan DT, Valiante NM. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2003;2(9):727-35
- Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007;5(7):505-17
- Gonçalves ED, Bonato VL, da Fonseca DM, et al. Improve protective efficacy of a TB DNA-HSP65 vaccine by BCG priming. Genet Vaccines Ther 2007;5-7
- Bloom BR. Tuberculosis: Pathogenesis, Protection, and Control. American Society for Microbiology. Washington DC: 1994. p. 531-57
- Tuomela M, Stanescu I, Krohn K. Validation overview of bio-analytical methods. Gene Ther 2005;12(Suppl 1):S131-38
- Portaro FC, Hayashi MA, De Arauz LJ, et al. The Mycobacterium leprae hsp65 displays proteolytic activity. Mutagenesis studies indicate that the M leprae hsp65 proteolytic activity is catalytically related to the HslVU protease. Biochemistry 2002;41(23):7400-06
- Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965;13(1):238-52
- Kirby CJ, Gregoriadis G. Preparation of liposomes containing factor VIII for oral treatment of haemophilia. J Microencapsul 1984;1(1):33-45
- Weibel ER. Models of Lung disease-microscopy and structural methods. Morphometry: stereological theory and practical methods 1990;199-247
- Silva CL, Bonato VL, Coelho-Castelo AA, et al. Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice. Gene Ther 2005;12(3):281-87
- Silva CL, Bonato VL, Lima VM, et al. Characterization of the memory/activated T cells that mediate the long-lived host response against tuberculosis after bacillus Calmette-Guerin or DNA vaccination. Immunology 1999;97(4):573-81
- Fauci AS. Multidrug-resistant and extensively drug-resistant tuberculosis: The National Institute of Allergy and Infectious Diseases research agenda and recommendations for priority research. J Infect Dis 2008;197:1493-8
- Skeiky YA, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 2006;4(6):469-76
- Lima KM, dos Santos SA, Santos RR, et al. Efficacy of DNA-hsp65 vaccination for tuberculosis varies with method of DNA introduction in vivo. Vaccine 2003;22(1):49-56
- Ruberti M, De Melo LK, dos Santos SA, et al. Prime–boost vaccination based on DNA and protein-loaded microspheres for tuberculosis prevention. J Drug Target 2004;12(4):195-203
- de Paula L, Silva CL, Carlos D, et al. Comparison of different delivery systems of DNA vaccination for the induction of protection against tuberculosis in mice and guinea pigs. Genet Vaccines Ther 2007;5:2 published online 24 January 2007, doi:10.1186/1479-0556-5-2
- Rosada RS, Gaziola de la Torre L, Frantz FG, et al. Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes. BMC Immunol 2008 (In Press)
- Twigg HL III. Humoral immune defense (antibodies): recent advances. Proc Am Thorac Soc 2005;2(5):417-21
- Bonato VL, Lima VM, Tascon RE, et al. Identification and characterization of protective T cells in hsp65 DNA-vaccinated and Mycobacterium tuberculosis-infected mice. Infect Immun 1998;66(1):169-75
- Palliser D, Huang Q, Hacohen N, et al. A role for Toll-like receptor 4 in dendritic cell activation and cytolytic CD8+ T cell differentiation in response to a recombinant heat shock fusion protein. J Immunol 2004;172(5):2885-93
- Palliser D, Guillen E, Ju M, et al. Multiple intracellular routes in the cross-presentation of a soluble protein by murine dendritic cells. J Immunol 2005;174(4):1879-87
- Lu S, Wang S, Grimes-Serrano JM. Current Progress of DNA vaccine studies in animals. Expert Rev Vaccines 2008;7(2):175-92
- Coelho-Castelo AAM, Trombone AP, Rosada RS, et al. Tissue distribution of a plasmid DNA encoding Hsp65 gene is dependent on the dose administered through intramuscular delivery. Genet Vaccines Ther 2006;30(4):1-10
- Michaluart P, Abdalhan KA Lima FD, et al. Phase I trial of DNA-hsp65 immunotherapy for advanced squamous cell carcinoma of the head and neck. Cancer Gene Ther 2008; published online 6 June 2008 doi: 10.1038/cgt.2008.35
- Andersen P. TB vaccines: progress and problems. Trends Immunol 2001;22(3):160-68
- Sierra VG. Is a new tuberculosis vaccine necessary and feasible? A Cuban opinion. Tuberculosis (Edinb) 2006;86(3-4):169-78
- Roth AE, Stensballe LG, Garly ML, et al. Beneficial non-targeted effects of BCG ethical implications for the coming introduction of new TB vaccines. Tuberculosis (Edinb) 2006;86(6):397-03
- Antas PRZ, Castello-Branco LRR. New vaccines against tuberculosis: lessons learned from BCG immunisation in Brazil. Transa. of the Royal Soc. of Trop. Medicine and Hygiene 2008;102(7):628-30